Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis
Authors
Keywords
-
Journal
JAMA Neurology
Volume -, Issue -, Pages -
Publisher
American Medical Association (AMA)
Online
2021-08-16
DOI
10.1001/jamaneurol.2021.2738
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
- (2020) Anna He et al. LANCET NEUROLOGY
- Aggressive multiple sclerosis (2): Treatment
- (2020) Georgina Arrambide et al. Multiple Sclerosis Journal
- Aggressive multiple sclerosis (1): Towards a definition of the phenotype
- (2020) Ellen Iacobaeus et al. Multiple Sclerosis Journal
- Comorbidity in Multiple Sclerosis
- (2020) Melinda Magyari et al. Frontiers in Neurology
- Comparative effectiveness of teriflunomide and dimethyl fumarate
- (2019) Mathias Due Buron et al. NEUROLOGY
- Contribution of smoking and alcohol consumption to income differences in life expectancy: evidence using Danish, Finnish, Norwegian and Swedish register data
- (2019) Olof Östergren et al. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH
- Current therapeutic landscape in multiple sclerosis
- (2019) Bruce A.C. Cree et al. CURRENT OPINION IN NEUROLOGY
- Unknown
- (2018) ACTA NEUROLOGICA SCANDINAVICA
- Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
- (2018) Mathias Granqvist et al. JAMA Neurology
- Common comorbidities and survival in MS: Risk for stroke, type 1 diabetes and infections
- (2018) A. Murtonen et al. Multiple Sclerosis and Related Disorders
- Unknown
- (2018) EUROPEAN JOURNAL OF NEUROLOGY
- Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study
- (2018) Francesco Saccà et al. Multiple Sclerosis Journal
- Validation of the Swedish multiple sclerosis register
- (2018) P Alping et al. EPIDEMIOLOGY
- Unknown
- (2017) EUROPEAN JOURNAL OF NEUROLOGY
- Evolving concepts in the treatment of relapsing multiple sclerosis
- (2017) Giancarlo Comi et al. LANCET
- Treatment decisions in multiple sclerosis — insights from real-world observational studies
- (2017) Maria Trojano et al. Nature Reviews Neurology
- Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
- (2016) Peter Alping et al. ANNALS OF NEUROLOGY
- Personalised medicine for multiple sclerosis care
- (2016) Arie Gafson et al. Multiple Sclerosis Journal
- Personalised medicine for multiple sclerosis care
- (2016) Arie Gafson et al. Multiple Sclerosis Journal
- Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up
- (2016) Carrie M. Hersh et al. Multiple Sclerosis and Related Disorders
- The Swedish MS registry - clinical support tool and scientific resource
- (2015) J. Hillert et al. ACTA NEUROLOGICA SCANDINAVICA
- Optimizing treatment success in multiple sclerosis
- (2015) Tjalf Ziemssen et al. JOURNAL OF NEUROLOGY
- Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis
- (2015) Jens Ingwersen et al. Neurotherapeutics
- Multiple Sclerosis in Older Adults: The Clinical Profile and Impact of Interferon Beta Treatment
- (2015) Afsaneh Shirani et al. Biomed Research International
- Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis
- (2014) Sandra Meyer-Moock et al. BMC Neurology
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison
- (2013) Michael Hutchinson et al. CURRENT MEDICAL RESEARCH AND OPINION
- Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study
- (2012) Virginia Devonshire et al. LANCET NEUROLOGY
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple sclerosis: current treatment algorithms
- (2011) Jordi Río et al. CURRENT OPINION IN NEUROLOGY
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
- (2009) Paul O'Connor et al. LANCET NEUROLOGY
- Efficacy of treatment of MS with IFN -1b or glatiramer acetate by monthly brain MRI in the BECOME study
- (2009) D. Cadavid et al. NEUROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started